Relapsed/Refractory T-cell Lymphomas
1 clinical trials · Condition
◉ Watch Relapsed/Refractory T-cell Lymphomas
| Record | Firm | Date |
|---|---|---|
| Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas (NCT02783625) | Memorial Sloan Kettering Cancer Center | 2016-05-23 |
Track Relapsed/Refractory T-cell Lymphomas automatically
Every clearance here is in the API, with alerts when new ones post.